Similar articles for PMID: 12468514

Year	Number of Results
1991	1
1993	1
1994	2
1995	2
1996	5
1997	9
1998	5
1999	6
2000	5
2001	3
2002	3
2003	1
2004	2
2005	3
2006	5
2007	2
2008	1
2009	1
2011	1
2023	0

1

Sigma receptor scintigraphy with N-[2-(1'-piperidinyl)ethyl]-3-(123)I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results.

Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A. Caveliers V, et al. J Nucl Med. 2002 Dec;43(12):1647-9. J Nucl Med. 2002. PMID: 12468514 Free article.

2

Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer.

John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, Wahl RL. John CS, et al. Nucl Med Biol. 1999 May;26(4):377-82. doi: 10.1016/s0969-8051(98)00104-8. Nucl Med Biol. 1999. PMID: 10382840

3

Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors.

John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. John CS, et al. Cancer Res. 1999 Sep 15;59(18):4578-83. Cancer Res. 1999. PMID: 10493511

4

Sigma-receptor imaging by means of I123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer.

Everaert H, Flamen P, Franken PR, Verhaeghe W, Bossuyt A. Everaert H, et al. Anticancer Res. 1997 May-Jun;17(3B):1577-82. Anticancer Res. 1997. PMID: 9179197

5

Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer.

John CS, Vilner BJ, Gulden ME, Efange SM, Langason RB, Moody TW, Bowen WD. John CS, et al. Cancer Res. 1995 Jul 15;55(14):3022-7. Cancer Res. 1995. PMID: 7606722

6

Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker.

Hou C, Tu Z, Mach R, Kung HF, Kung MP. Hou C, et al. Nucl Med Biol. 2006 Feb;33(2):203-9. doi: 10.1016/j.nucmedbio.2005.10.001. Nucl Med Biol. 2006. PMID: 16546674

7

Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells.

John CS, Vilner BJ, Bowen WD. John CS, et al. J Med Chem. 1994 Jun 10;37(12):1737-9. doi: 10.1021/jm00038a002. J Med Chem. 1994. PMID: 8021913 No abstract available.

8

[Assessement of the usefulness of whole body scintigraphy after administration of 6 MBq of 131I in the diagnostic of breast cancer].

Gołkowski F, Sokołowski G, Gil J, Kostecka-Matyja M, Basta P, Sowa-Staszczak A, Szybiński Z, Hubalewska-Dydejczyk A. Gołkowski F, et al. Przegl Lek. 2011;68(2):92-5. Przegl Lek. 2011. PMID: 21751517 Polish.

9

Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.

Larisch R, Schulte KW, Vosberg H, Ruzicka T, Müller-Gärtner HW. Larisch R, et al. J Nucl Med. 1998 Jun;39(6):996-1001. J Nucl Med. 1998. PMID: 9627332 Free article.

10

Substituted halogenated arylsulfonamides: a new class of sigma receptor binding tumor imaging agents.

John CS, Lim BB, Vilner BJ, Geyer BC, Bowen WD. John CS, et al. J Med Chem. 1998 Jul 2;41(14):2445-50. doi: 10.1021/jm9800447. J Med Chem. 1998. PMID: 9651150

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed